The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is currently seeking a motivated individual to be our Manager of Accounting & Financial Reporting, responsible for SEC reporting, technical accounting, SOX and internal audit, clinical trial accounting, equity administration, contract administration, and other key financial reporting items.